Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does PEMBROLIZUMAB Cause Performance status decreased? 54 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 54 reports of Performance status decreased have been filed in association with PEMBROLIZUMAB (KEYTRUDA). This represents 0.1% of all adverse event reports for PEMBROLIZUMAB.

54
Reports of Performance status decreased with PEMBROLIZUMAB
0.1%
of all PEMBROLIZUMAB reports
12
Deaths
27
Hospitalizations

How Dangerous Is Performance status decreased From PEMBROLIZUMAB?

Of the 54 reports, 12 (22.2%) resulted in death, 27 (50.0%) required hospitalization, and 10 (18.5%) were considered life-threatening.

Is Performance status decreased Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for PEMBROLIZUMAB. However, 54 reports have been filed with the FAERS database.

What Other Side Effects Does PEMBROLIZUMAB Cause?

Malignant neoplasm progression (10,111) Death (4,744) Diarrhoea (4,251) Fatigue (3,833) Off label use (3,416) Product use in unapproved indication (3,191) Pyrexia (3,155) Rash (2,900) Nausea (2,670) Decreased appetite (2,486)

What Other Drugs Cause Performance status decreased?

BACLOFEN (156) LENALIDOMIDE (118) PACLITAXEL (112) BEVACIZUMAB (103) SODIUM OXYBATE (103) CARBOPLATIN (100) DEXAMETHASONE (80) CAPECITABINE (75) NIRAPARIB (75) LUMATEPERONE (68)

Which PEMBROLIZUMAB Alternatives Have Lower Performance status decreased Risk?

PEMBROLIZUMAB vs PEMETREXED PEMBROLIZUMAB vs PEMIGATINIB PEMBROLIZUMAB vs PENICILLAMINE PEMBROLIZUMAB vs PENICILLIN PEMBROLIZUMAB vs PENICILLIN G

Related Pages

PEMBROLIZUMAB Full Profile All Performance status decreased Reports All Drugs Causing Performance status decreased PEMBROLIZUMAB Demographics